Lezack Adam sold 998 shares of Beta Bionics, Inc. on May 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed May 26, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
998Comon Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
3.51%This security and ownership context
Holdings after
27,399Direct
Trade date
May 22, 2026Sell
Filed
May 26, 2026, 6:00 PM ET4-day reporting delay
Accession
0002048466-26-000003Code S · Transaction 385716
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 28,397 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 21, 2026Sell1,000$9.95−$9,950Trade 385714
May 21, 2026Grant16,965$0.00$0Trade 385715
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

BBNX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BBNX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +4.1%1w ago −19%1d ago −9.5%
Returns since7d +9.1%30d +36%90d +68%180d1y

Footnotes in full

F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F2: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.